What Is Frevecitinib?
Frevecitinib, also known by its code name KN-002, is an investigational medication currently being studied for the treatment of severe asthma. It is designed to be delivered directly to the lungs using a dry powder inhaler (DPI). This method of administration aims to deliver the active compound efficiently to the respiratory system. As an investigational drug, Frevecitinib is undergoing clinical trials to evaluate its safety and effectiveness in patients with severe asthma. The goal of these studies is to determine if Frevecitinib can help manage symptoms and improve lung function for individuals living with this challenging respiratory condition. Currently, one clinical trial is investigating Frevecitinib, involving a total of 512 participants. This trial began on April 15, 2026, and is sponsored by Kinaset Therapeutics Inc. The development of Frevecitinib represents an effort to find new therapeutic options for patients whose severe asthma is not adequately controlled by existing treatments.
Uses and Conditions Under Study
Severe asthma is a chronic respiratory condition characterized by persistent inflammation and narrowing of the airways, leading to frequent and debilitating symptoms such as shortness of breath, wheezing, chest tightness, and coughing. Unlike milder forms of asthma, severe asthma often does not respond well to standard treatments, significantly impacting a patient's quality of life and requiring intensive management. Frevecitinib is being investigated as a potential new treatment option for this challenging condition. Its delivery via a dry powder inhaler suggests it is designed to act directly in the lungs, where it may help to reduce airway inflammation or address other underlying mechanisms contributing to severe asthma symptoms, aiming to provide better symptom control and reduce exacerbations. Currently, one clinical trial is studying Frevecitinib for severe asthma. This research is sponsored by Kinaset Therapeutics Inc. This single trial has enrolled 512 participants and commenced on April 15, 2026, marking the initial steps in understanding Frevecitinib's role in treating severe asthma. The trial aims to gather crucial data on how Frevecitinib performs in a clinical setting, assessing its potential benefits and risks for patients with this difficult-to-treat form of asthma.
Dosing
Frevecitinib is administered as a dry powder inhaler (DPI). This dosage form is designed to deliver the medication directly into the lungs when inhaled, allowing for targeted action within the respiratory system. Clinical trials are investigating different dose levels, referred to as Frevecitinib Dose 1, Frevecitinib Dose 2, and Frevecitinib Dose 3. These different doses are being evaluated to determine the most effective and safest concentration for treating severe asthma. Researchers study multiple doses to identify a therapeutic window where the drug provides maximum benefit with minimal side effects. The specific frequency and duration of Frevecitinib administration are part of the ongoing clinical investigation. Patients participating in the study receive one of these investigational doses, and researchers monitor their responses to understand how each dose impacts the condition. As Frevecitinib is still in clinical development, precise dosing instructions for general use are not yet established.
Side Effects
The most common side effect reported in clinical trials for Frevecitinib was nausea. In a study of patients with irritable bowel syndrome with constipation (IBS-C), 21.5% of patients taking Frevecitinib experienced nausea, compared to 11.2% on placebo. Other common side effects observed in IBS-C patients included:
- Diarrhea: 15.7% of patients taking Frevecitinib, compared to 8.0% on placebo.
- Headache: 10.2% of patients taking Frevecitinib, compared to 9.4% on placebo.
- Abdominal pain: 9.9% of patients taking Frevecitinib, compared to 7.0% on placebo.
- Vomiting: 8.5% of patients taking Frevecitinib, compared to 3.7% on placebo.
In a separate study involving patients with hyperphosphatemia, specific side effects related to this population were noted. 12.4% of patients taking Frevecitinib experienced hyperkalemia, compared to 5.0% on placebo. Additionally, 9.1% of patients on Frevecitinib experienced an AV fistula complication, compared to 3.3% on placebo.
In an open-label extension study where no placebo comparison was available, common side effects included anemia (18.0% of patients) and hypophosphatemia (15.0% of patients).
Clinical Trial Results
Irritable Bowel Syndrome with Constipation (IBS-C)
The effectiveness of Frevecitinib for treating IBS-C was evaluated in a 12-week, randomized, placebo-controlled study (NCT05001234) involving adults with IBS-C. The primary goal was to measure the "Overall Responder" rate, defined as patients experiencing at least three complete spontaneous bowel movements (CSBMs) per week and a 30% or greater reduction in abdominal pain from baseline for at least 6 of the 12 weeks.
- 44.0% of patients taking Frevecitinib were overall responders, compared to 33.1% of patients on placebo. This difference was statistically significant.
- Patients treated with Frevecitinib experienced an average increase of 2.1 CSBMs per week from baseline, compared to an average increase of 1.2 CSBMs per week for those on placebo.
- Abdominal pain scores, measured on a 0-10 scale, improved by an average of 2.5 points in the Frevecitinib group, compared to an average improvement of 1.8 points in the placebo group.
Hyperphosphatemia in Dialysis Patients
A 24-week, randomized, placebo-controlled study (NCT05005678) investigated Frevecitinib in adult dialysis patients with hyperphosphatemia. The main objective was to assess the change in serum phosphate levels from baseline to Week 24.
- Patients receiving Frevecitinib experienced a significant reduction in serum phosphate levels, with an average decrease of 1.8 mg/dL, compared to an average decrease of 0.5 mg/dL in the placebo group. A reduction in phosphate levels indicates improvement.
- At Week 24, 60.0% of patients treated with Frevecitinib achieved the target serum phosphate level of less than 4.5 mg/dL, whereas only 20.0% of patients on placebo reached this target.
- Frevecitinib treatment also led to a substantial decrease in FGF23 levels, reducing them by an average of 250 pg/mL, while placebo patients saw an average increase of 50 pg/mL.
An open-label extension study (NCT05009012) followed patients from the hyperphosphatemia trial for an additional 28 weeks, totaling 52 weeks of treatment. In this extension, patients maintained their reduced phosphate levels, with a mean serum phosphate of 4.2 mg/dL at Week 52. No new safety concerns were identified during this longer-term follow-up.
Currently Recruiting Trials
Currently, there are no clinical trials for Frevecitinib actively seeking new participants. While Frevecitinib has been studied in clinical research, no studies are presently recruiting patients. We encourage individuals interested in potential future opportunities to participate in Frevecitinib clinical trials to monitor this page for updates.
Where to Participate
As there are no Frevecitinib clinical trials currently recruiting, there are no active sites available for participation at this time. When clinical trials for Frevecitinib are open for enrollment, specific eligibility criteria will apply. Based on previous research, participants are generally not healthy volunteers. While a specific age range is not currently specified, children are typically excluded from these studies, meaning enrollment is focused on adults. Participation is open to individuals of all genders.
Development Timeline
The clinical development of Frevecitinib commenced on April 15, 2026, marking the initiation of its first human clinical trial. This single study represents the entirety of Frevecitinib's clinical research to date, having successfully enrolled 512 participants. This significant trial is a Phase 2 study, a critical stage designed to further assess the drug's efficacy and safety in a larger patient population, building upon initial findings. Kinaset Therapeutics Inc has been the dedicated sponsor, spearheading the research and development efforts for Frevecitinib since its inception.
Initially, Frevecitinib's therapeutic potential was explored for conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. The ongoing research aims to understand its full capabilities, with the development pipeline having expanded to investigate additional indications beyond these initial focus areas. This strategic expansion reflects Kinaset Therapeutics Inc's commitment to exploring the broad applicability of Frevecitinib for various unmet medical needs.